Ryusei Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryusei Yamamoto has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Nobuyuki Watanabe
Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publicationsShoji Kawakatsu
Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publicationsShunsuke Onoe
Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publicationsTaisuke Baba
Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publicationsYoshie Shimoyama
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publicationsAtsushi Ogura
Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication
Latest Publications
- 25 June 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Radial Margin Distance in Perihilar Cholangiocarcinoma
Objective: To evaluate the prognostic impact of radial margin distance (RMD) in patients with perihilar cholangiocarcinoma (pCCA) and establish clinically relevant cutoff values. Background: A positive radial margin is conventionally defined by cancer cell exposure at the transection plane. However, a standardized classification for pCCA has yet to be established. Methods: pCCA patients who underwent tumor resection between 2005 and 2020 were retrospectively analyzed. The relationships between histologically measured RMDs and long-term outcomes were examined. Results: Among the 658 study patients, the median RMD was 0.4 mm (interquartile range, 0.1–1.1 mm). The hazard for overall survival peaked at an RMD of 0 mm (conventional cutoff), decreased with increasing RMD, and plateaued at approximately 1.0 mm, which was identified as the optimal threshold in rank statistics (|z|, 11.09; P 0–P P P P 0–P <0.001) were independent predictors of poor overall survival. Conclusions: RMD assessment with dual cutoffs of 0 and 1.0 mm was simple and clinically relevant and effectively stratified postoperative recurrence risk and survival in pCCA patients.
- 25 June 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Radial Margin Distance in Perihilar Cholangiocarcinoma
Objective: To evaluate the prognostic impact of radial margin distance (RMD) in patients with perihilar cholangiocarcinoma (pCCA) and establish clinically relevant cutoff values. Background: A positive radial margin is conventionally defined by cancer cell exposure at the transection plane. However, a standardized classification for pCCA has yet to be established. Methods: pCCA patients who underwent tumor resection between 2005 and 2020 were retrospectively analyzed. The relationships between histologically measured RMDs and long-term outcomes were examined. Results: Among the 658 study patients, the median RMD was 0.4 mm (interquartile range, 0.1–1.1 mm). The hazard for overall survival peaked at an RMD of 0 mm (conventional cutoff), decreased with increasing RMD, and plateaued at approximately 1.0 mm, which was identified as the optimal threshold in rank statistics (|z|, 11.09; P 0–P P P P 0–P <0.001) were independent predictors of poor overall survival. Conclusions: RMD assessment with dual cutoffs of 0 and 1.0 mm was simple and clinically relevant and effectively stratified postoperative recurrence risk and survival in pCCA patients.
- 25 August 2025
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (11) , 838-846
Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct
Background: Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear. Methods: This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi‐quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2‐negative and HER2‐positive groups, respectively. Results: A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2‐positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2‐positive group. The HER2‐positive group demonstrated significantly worse overall survival than the HER2‐negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors. Conclusion: HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.
- 25 August 2025
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (11) , 838-846
Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct
Background: Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear. Methods: This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi‐quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2‐negative and HER2‐positive groups, respectively. Results: A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2‐positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2‐positive group. The HER2‐positive group demonstrated significantly worse overall survival than the HER2‐negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors. Conclusion: HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.